Raleigh Capital Management Inc. Intra Cellular Therapies, Inc. Transaction History

Raleigh Capital Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 21, 2024	BUY	$46.37 - $73.65 $185 - $294	4 Added 3.88%	107 $7,000
Q3 2023 Dec 06, 2023	BUY	$52.09 - $64.1 $2,187 - $2,692	42 Added 68.85%	103 $5,000
Q2 2023 Jul 25, 2023	BUY	$54.67 - $66.44 $1,093 - $1,328	20 Added 48.78%	61 $3,000
Q1 2023 May 22, 2023	BUY	$43.8 - $56.99 $394 - $512	9 Added 28.13%	41 $2,000
Q4 2022 Feb 07, 2023	BUY	$44.07 - $54.45 $705 - $871	16 Added 100.0%	32 $1,000
Q3 2022 Nov 09, 2022	BUY	$42.7 - $59.99 $683 - $959	16 New	16 $1,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Raleigh Capital Management Inc. with notifications on news.